Cingulate (CING) Projected to Announce Quarterly Earnings on Thursday

Cingulate (NASDAQ:CING) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $0.54 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

Cingulate (NASDAQ:CING) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.18. On average, analysts expect Cingulate to post ($2.19) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Cingulate Trading Up 4.5%

Shares of CING stock opened at $4.45 on Tuesday. The firm has a 50-day moving average of $4.91 and a 200-day moving average of $5.41. Cingulate has a one year low of $3.16 and a one year high of $11.89.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Weiss Ratings cut shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Wall Street Zen cut Cingulate from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Roth Capital set a $9.00 target price on Cingulate and gave the stock a “buy” rating in a research note on Sunday, August 23rd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cingulate currently has an average rating of “Moderate Buy” and an average price target of $27.00.

Cingulate Company Profile

Cingulate Inc (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient.